Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias

Patent metadata

Field	Value
Publication number	US-10231985-B2
Application number	US-201415028139-A
Country	US
Kind code	B2
Filing date	Oct 8, 2014
Priority date	Oct 8, 2013
Publication date	Mar 19, 2019
Grant date	Mar 19, 2019

Abstract

The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.

First claim

The invention claimed is:

1. A method for symptomatically treating, or for delaying or slowing progression of dyslipidemia linked to the excess presence of fatty acids in biological membranes of a human subject suffering from type 2 diabetes mellitus or metabolic syndrome comprising administering to the subject a derivative of unsaturated fatty acid or fatty acid amide compound consisting of an effective amount of mannide monooleate, 3-hydroxy-2,2-bis(hydroxymethyl)propyl oleate or N,N-diethanololeamide.

2. The method according to claim 1 , wherein the method is characterized in that dyslipidemia is responsible for the lipointoxication, dysfunction or apoptosis of non-adipocyte cells by decreasing or suppressing the fluidity of plasma membranes and/or organelle membranes of said non-adipocyte cells.

3. The method according to claim 1 , wherein the method is characterized in that the compound is nontoxic to cells unable to synthesize neutral lipids.

4. The method according to claim 1 , wherein the dyslipidemia is associated with the presence of metabolic syndrome.

5. The method according to claim 4 , wherein or symptomatically treats or reduces at least one symptom of metabolic syndrome said method symptomatically treats or reduces at least one symptom of metabolic syndrome selected from the group consisting of insulin resistance, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, hypertension, heart failure and hepatic steatosis.

6. The method according to claim 1 , wherein the method comprises administering said compound in combination with a biguanide, glitazone, sulfonamide-based hypoglycemic, glinide, DPP-4 inhibitor, incretin mimetic or α-glucosidase inhibitor.

7. The method according to claim 1 , wherein said compound i) does not allow the production of diunsaturated phospholipids in the membrane of the cells in the subject, ii) does not constitute a source of oleic acid for the cells in the subject and iii) does not induce intracellular calcium mobilization and/or is not degraded by lipases.

Assignees

• Centre Nat Rech Scient
• Univ Poitiers
• Univ Exeter

Inventors

• Spanova Miroslava
• Ferreira Thierry
• Clement Romain
• Dhayal Shalinee
• Morgan Noël

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title